- Home
- WBX vs PLRX Comparison
WBX vs PLRX Comparison
Compare WBX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- PLRX
- Stock Information
- Founded
- WBX 2015
- PLRX 2015
- Country
- WBX Spain
- PLRX United States
- Employees
- WBX N/A
- PLRX N/A
- Industry
- WBX Industrial Specialties
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- WBX Consumer Discretionary
- PLRX Health Care
- Exchange
- WBX Nasdaq
- PLRX Nasdaq
- Market Cap
- WBX 85.1M
- PLRX 77.3M
- IPO Year
- WBX N/A
- PLRX 2020
- Fundamental
- Price
- WBX $5.93
- PLRX $1.44
- Analyst Decision
- WBX Buy
- PLRX Hold
- Analyst Count
- WBX 3
- PLRX 10
- Target Price
- WBX $14.33
- PLRX $9.79
- AVG Volume (30 Days)
- WBX 18.7K
- PLRX 1.7M
- Earning Date
- WBX 07-31-2025
- PLRX 08-06-2025
- Dividend Yield
- WBX N/A
- PLRX N/A
- EPS Growth
- WBX N/A
- PLRX N/A
- EPS
- WBX N/A
- PLRX N/A
- Revenue
- WBX $171,352,140.00
- PLRX N/A
- Revenue This Year
- WBX N/A
- PLRX N/A
- Revenue Next Year
- WBX $44.10
- PLRX N/A
- P/E Ratio
- WBX N/A
- PLRX N/A
- Revenue Growth
- WBX 3.75
- PLRX N/A
- 52 Week Low
- WBX $4.60
- PLRX $1.10
- 52 Week High
- WBX $32.80
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- WBX 83.14
- PLRX 54.38
- Support Level
- WBX $5.92
- PLRX $1.32
- Resistance Level
- WBX $6.25
- PLRX $1.48
- Average True Range (ATR)
- WBX 0.26
- PLRX 0.11
- MACD
- WBX 0.20
- PLRX 0.02
- Stochastic Oscillator
- WBX 91.95
- PLRX 78.08
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.